ABEO at a glance
ABEONA THERAPEUTICS INC. (ABEO, SEC CIK 318306) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 15, 2026 and Form 4 insider filings as recently as September 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ABEONA THERAPEUTICS INC. (ABEO) reported revenue of $5.8 million (up 37.1% from FY2024) and net income of $71.2 million. Diluted EPS was $1.01.
- The most recent insider open-market sale reported on Form 4 was by Vazzano Joseph Walter on September 29, 2026 of 9,191 shares at $5.16 per share.
- In the last 90 days, ABEO insiders reported 0 open-market purchases ($0) and 10 open-market sales ($1.1M) on Form 4, a net sale of $1.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.8M
- +37.1% vs prior year
- Insiders · 90 days
- 0 buys · 10 sells
- Net −$1.1M
- Latest 8-K
- Sep 15, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $11.4M, up $11.0M YoY, driven by ZEVASKYN product revenue
- ZEVASKYN best-performing line at $11.4M revenue; license revenue declined to $0 from $0.4M
- Operating loss $13.7M vs $22.8M YoY; operating margin -120.0% vs -5,698.0%
- Cash resources $146.8M at June 30, 2026; six-month operating cash outflow $37.3M
- Outlook: cash sufficient for at least 12 months, but additional funding may be needed; losses expected for several years
Risk Factors
- July 2026 cellular identity test out of specification blocked commercial release of one ZEVASKYN batch
- FDA-authorized single-patient IND release, while commercial authorization remains unavailable
- FDA specification-revision acceptance uncertain, creating regulatory compliance risk
- Autologous biopsy viability and cell proliferation delays may require repeat manufacturing
- August 2025 false-positive sterility assay caused manufacturing rejection and delayed launch
AI summary of the ABEO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Section 7.01 language contains only standard Regulation FD liability and incorporation disclaimers
- No substantive business, clinical, financial, or market-moving disclosure in the provided text
Item 2.02: Results of Operations and Financial Condition
- Section 2.02 text contains only legal safe-harbor language
- No fiscal-year 2026 financial results or operating metrics disclosed
Item EX-99.1: Item EX-99.1
- Q2 ZEVASKYN revenue $11.4M, up 31% quarter-over-quarter from $8.7M, signaling early commercial traction
- Five Q2 treatments and 12 since launch, but two treatments generated no revenue due to manufacturing yield or lot-release issues
Item 5.07: Submission of Matters to a Vote of Security Holders
- Keith A. Goldan and Bernhardt G. Zeiher, M.D. elected Class 1 directors through 2029
- Executive compensation approved in advisory vote, 23,300,653 votes for versus 4,511,866 against
AI summaries of ABEO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ABEO
Don't miss the next ABEO filing
- Alerts as it files. A push when ABEO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ABEO, by share count.
- Ask anything. An AI agent that reads every ABEO filing and answers with sources.
ABEO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Vazzano Joseph Walter | Sell | Sep 29, 2026 | 9,191 | $5.16 |
| Seshadri Vishwas | Sell | Sep 29, 2026 | 19,608 | $5.16 |
| O'Malley Brendan M. | Sell | Sep 29, 2026 | 6,727 | $5.16 |
| Vasanthavada Madhav | Sell | Sep 29, 2026 | 4,902 | $5.16 |
| Alvino Mark | Sell | Sep 1, 2026 | 15,000 | $5.86 |
| Vazzano Joseph Walter | Sell | Jul 21, 2026 | 1,478 | $6.53 |
| Seshadri Vishwas | Sell | Jul 9, 2026 | 67,971 | $6.96 |
| Vasanthavada Madhav | Sell | Jul 9, 2026 | 12,606 | $6.96 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.2M | $5.8M |
| Operating Income | - | -$64.2M | -$89.4M |
| Net Income | -$54.2M | -$63.7M | $71.2M |
| Op. Margin | - | -1512.3% | -1536.9% |
| Net Margin | - | -1501.0% | 1223.1% |
| Balance Sheet | |||
| Total Assets | $64.0M | $108.9M | $219.6M |
| Equity | - | $44.0M | $159.2M |
| ROE | - | -144.7% | 44.7% |
| Per Share | |||
| EPS | $-2.53 | $-1.55 | $1.01 |
| Cash Flow | |||
| Operating CF | - | -$56.0M | -$76.3M |
| CapEx | $331K | $2.4M | $8.0M |
Source: XBRL data in ABEONA THERAPEUTICS INC. (ABEO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
ABEO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Sep 1, 2026 | - | - | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | May 26, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
ABEO SEC filings: frequently asked questions
Are ABEO insiders buying or selling?
In the last 90 days, ABEONA THERAPEUTICS INC. (ABEO) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $1.1 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
What was ABEO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ABEONA THERAPEUTICS INC. (ABEO) reported revenue of $5.8 million (up 37.1% from FY2024) and net income of $71.2 million. Diluted EPS was $1.01. The figures come from the XBRL data in the 10-K.
What did ABEO report in its latest 8-K?
ABEONA THERAPEUTICS INC. (ABEO) filed an 8-K on September 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). Section 7.01 language contains only standard Regulation FD liability and incorporation disclaimers.
What are the latest ABEO SEC filings?
ABEONA THERAPEUTICS INC. (ABEO) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 15, 2026 and a Form 4 insider filing on September 29, 2026.
What is ABEO's SEC CIK number?
ABEONA THERAPEUTICS INC. (ABEO)'s SEC Central Index Key (CIK) is 318306. EDGAR lists every ABEO filing under that number.
Ask anything about ABEO
The research agent reads ABEO's filings, financials, insider trades and 13F holders, then answers with sources.